Browsing by Author "Akyildiz, Murat"

Now showing 1 - 3 of 3

Outcomes Following Deceased and Live Donor Liver Transplantation for the Indication of Acute Liver Failure: A Multicenter Experience
(2020) Turan, Ilker; Aladag, Murat; Harputluoglu, Murat; Yilmaz, Sezai; Gencdal, Genco; Polat, Kamil Yalcin; Ozcay, Figen; Akarsu, Mesut; Unek, Tarkan; Karasu, Zeki; Zeytunlu, Murat; Sumer, Hale Gokcan; Bostanci, Erdal Birol; Kartal, Aysun Caliskan; Balci, Deniz; Dayangac, Murat; Dincer, Dinc; Adanir, Haydar; Dursun, Hakan; Gulsen, Murat Taner; Gunduz, Feyza; Balaban, Hatice Yasemin; Kabacam, Gokhan; Akyildiz, Murat; Gunsar, Fulya; Akarca, Ulus; Gurakar, Ahmet; Idilman, Ramazan; 0000-0002-5214-516X; ABG-5684-2020
Right-lobe Liver Transplant From Donors With Gilbert Syndrome
(Başkent Üniversitesi, 2012-12) Demirbas, Tolga; Akyildiz, Murat; Yuzer, Yildiray; Tokat, Yaman; Yaprak, Onur; Dayangac, Murat; Piskin, Turgut
Objectives: Donor safety is one of the most important aspects of living-donor liver transplant. The preoperative evaluation of candidates for such transplants essentially starts with serologic and biochemical analyses. However, some potential liver donors with normal liver function test results may have isolated mild hyperbilirubinemia (serum indirect bilirubin level > 20.5 µmol/L [1.2 mg/dL]). Gilbert syndrome is an autosomal recessive condition that is a common cause of nonhemolytic unconjugated hyperbilirubinemia, and its prevalence is 3% to 10% in the healthy US population. Mild hyperbilirubinemia episodes are expected in people with Gilbert syndrome when they are exposed to physical stress, such as operative intervention or low energy intake. The liver morphologic findings of these individuals are normal; however, there is a debate on the use of people with Gilbert syndrome as living-liver donors. The purpose of this study was to assess the results of right-lobe living-donor hepatectomy of liver donors with Gilbert syndrome. Materials and Methods: Between 2004 and 2010, two hundred twenty-five living-donor liver transplants using right-lobe grafts were performed in our hospital. Donors with Gilbert syndrome were defined as those whose serum bilirubin level was greater than 20.5 µmol/L (1.2 mg/dL). Six of 225 right-lobe living-donor liver transplants were performed using donors with Gilbert syndrome. Results: The median follow-up after transplant was 34 months (range, 18 to 51 mo). One week after the operation, the median bilirubin level for right-lobe liver donors was 34.5 µmol/L (2.02 mg/dL) (range, 17.1 to 51.3 µmol/L [1 to 3 mg/dL]), and the median prothrombin time (international normalized ratio) was 1.36 (range, 1.1 to 1.7). The median bilirubin level of the donors after 6 months was 29 µmol/L (1.7 mg/dL) (range, 20.5 to 41 µmol/L [1.2 to 2.4 mg/dL]). Conclusions: Living-donor liver transplant from Gilbert syndrome donors can be safely performed.
A single-center experience: Liver biopsy results during a year
(2022) Meral, Cenk Emre; Gencdal, Genco; Akyildiz, Murat; Gunsar, Fulya; Nart, Deniz; Yilmaz, Funda; Karasu, Zeki; Ersoz, Galip; Akarca, Ulus Salih; 35783472
Background and Aim: Liver biopsy is the gold standard method for the diagnosis and treatment of liver diseases. In this study, we aimed to evaluate the results of liver biopsies performed in a year in our clinic. In addition, we also aimed if these liver biopsies could reveal the etiology of liver disease in patients with elevations of transaminases or/and alkaline phosphatase levels or liver masses. Materials and Methods: Patients who had liver biopsies for persistently elevated transaminases or/and alkaline phosphatase levels, protocol biopsies after liver transplantation, or liver masses in our hepatology clinic between 2011 and 2012 were included in the study. Liver biopsy decisions were made by experts during the hepatology council. Liver biopsies were previously performed using classical percutaneous liver biopsy or ultrasonography-guided Sonocan (R) liver biopsy sets. The pathology results of liver biopsies and clinical data of the matching patients were obtained from the liver biopsy record archives and patient files, respectively. Results: Totally, 479 liver biopsy results (male=252, 52.6%, mean age 49 +/- 14.5 years) were evaluated in the study. Of these patients, 432 (male=228) underwent percutaneous liver biopsy and 47 (male=24) underwent Sonocan (R) needle biopsy. The most common histopathologic diagnoses in the percutaneous liver biopsy group were chronic hepatitis B (n=127, 29.4%), normal histopathological findings (n=50, 11.6% and 32 of them were protocol biopsies after liver transplantation), and nonalcoholic steatohepatitis (NASH, n=41, 9.5%). The most common histopathologic diagnoses in the Sonocan (R) group were 25 liver metastasis out of 29 liver tumors (n=25, 53.2% of all) chronic hepatitis B (n=5, 10.6%), and NASH (n=3, 6.4%). Conclusion: In this study, diversity in liver biopsy results indicates the importance of histopathological evaluation. The most prevalent pathology in the liver biopsies was chronic hepatitis B, which is the most common chronic liver disease in Turkey. The metastatic liver tumor was the most common among the liver masses.